Effect of Fish Oil-based Intravenous Fat Emulsion with Parenteral Nutrition in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
- Author:
Ji Hyeong CHOE
1
;
Young Joo LEE
;
Hye Jung BAE
;
Sun Hoi JUNG
;
Hyeon Joo HAHN
;
Yungil KOH
Author Information
- Publication Type:Original Article
- Keywords: Fatty acids; Fish oils; Hematopoietic stem cell transplantation; Parenteral nutrition; total
- MeSH: Adult; Body Mass Index; Demography; Electronic Health Records; Fatty Acids; Fever; Fish Oils; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation*; Hematopoietic Stem Cells*; Humans; Incidence; Length of Stay; Mortality; Parenteral Nutrition*; Retrospective Studies; Sepsis; Weight Gain; Weight Loss
- From:Journal of Clinical Nutrition 2016;8(1):29-35
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE: Omega-3 fatty acid is known for immunonutrition in that it has anti-inflammatory properties and improves the patients' immune function. The objective of this study was to determine the effects of a fish oil-based lipid emulsion for adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). METHODS: This was a retrospective study of 90 adult allogeneic HSCT patients from July 2011 to June 2015. The patients were divided into two groups according to the lipid type provided; fish oil group (FO group, n=55) and non-fish oil group (NFO group, n=35). The demographics, parenteral nutrition and lipid emulsion duration, length of hospital stay (LOS), weight change, 30 day mortality, survival period, incidence of acute graft-versus-host disease (aGVHD), neutropenic fever, sepsis, and re-hospitalization were collected from the electronic medical records. RESULTS: The patients' characteristics including age, sex, body mass index, and underlying disease were similar in the two groups. The incidence of aGVHD and infectious complications, mortality, LOS, re-hospitalization were also similar. The FO group showed weight gains, whereas the NFO group showed weight loss (FO vs. NFO=0.34% vs. -1.08%, P=0.245). CONCLUSION: The clinical outcomes were similar in the two groups but there was a tendency for gain weight in the FO group. A large, well designed study, and a dosing study will also be needed to determine the optimal dose range for HSCT patients.
